Kosta Steliou is the chairman and CEO of PhenoMatriX, Inc., a Boston-based pharmaceutical company in Massachusetts focused on therapeutics for cancer and mitochondrial dysfunction in neurodegenerative diseases.
Dr. Steliou is professor emeritus of chemistry, research professor emeritus of pharmacology, and professor at the Cancer Research Center in the School of Medicine at Boston University. Prior to joining the faculty at Boston University, he was a member of the tenured faculty in the department of chemistry at the University of Montreal (Canada) from 1979-1993. He obtained his undergraduate (BSc) and postgraduate degrees (MSc, PhD) in chemistry from McGill University (Canada) and did postdoctoral studies from 1977-1979 at McGill University, the University of Leicester (England), the University of Copenhagen (Denmark), and Princeton University.
He is a member of numerous social and professional affiliations, has been a visiting professor at the University of Wisconsin, the Weizmann Institute of Science (Israel), the National Technical University (Greece), the University of Siena (Italy), the Democritos Research Center (Greece), and a visiting scientist at the Massachusetts General Hospital (Boston) in the department of medicine at the Center for Regenerative Medicine and Technology. He advises pharmaceutical and health-related companies in the areas of pharmacogenomics, synthetic chemistry, cancer, cardiovascular diseases and metabolic disorders. His research interests include epigenetic therapies for treating mitochondrial disease and neurodegenerative disorders, such as Alzheimer and Parkinson diseases, and the design and chemical synthesis of bioactive compounds for treating cancer and metabolic disorders. He is the principal author of more than 100 scientific peer-reviewed papers and patents, and is often invited to give lectures around the world.
Dr. Steliou serves on the advisory boards of PhenoMatriX, Inc. (PMX) and the Foundation for a Cure for Mitochondrial Disease (MitoCure). He is an elected Fellow (2013) of the American Association for the Advancement of Science (AAAS), a trustee of the Massachusetts Association of Scholars, a director of the New England Hellenic Medical and Dental Society and a member of the editorial advisory board of a number of scientific journals.